FDA Approves Genentech’s Enspryng for Neuromyeliti...
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng (satralizumab-mwge) as the subcutaneous treatment for adults living with anti-aquaporin...
August 17, 2020
6:17 am By Neha Mule